[go: up one dir, main page]

SI9400085A - Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza - Google Patents

Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza Download PDF

Info

Publication number
SI9400085A
SI9400085A SI9400085A SI9400085A SI9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A
Authority
SI
Slovenia
Prior art keywords
mpl
vaccine composition
protein
vaccine
composition according
Prior art date
Application number
SI9400085A
Other languages
English (en)
Slovenian (sl)
Inventor
Susan Dillon
Hirotoshi Nishikawa
Paul Dal Monte
Robert J Gyurick
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Biolog filed Critical Smithkline Beecham Corp
Publication of SI9400085A publication Critical patent/SI9400085A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI9400085A 1993-02-19 1994-02-18 Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza SI9400085A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US11575093A 1993-09-01 1993-09-01

Publications (1)

Publication Number Publication Date
SI9400085A true SI9400085A (en) 1994-09-30

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9400085A SI9400085A (en) 1993-02-19 1994-02-18 Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza

Country Status (9)

Country Link
EP (1) EP0684838A1 (fr)
AP (1) AP431A (fr)
AU (1) AU6141094A (fr)
CA (1) CA2156525A1 (fr)
IL (1) IL108681A0 (fr)
MA (1) MA23118A1 (fr)
MX (1) MX9401225A (fr)
SI (1) SI9400085A (fr)
WO (1) WO1994019013A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
EP1361889A1 (fr) * 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Nouveau vaccin
WO2002087494A2 (fr) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals, Sa Nouveau vaccin
SI1789084T1 (sl) 2004-09-09 2011-03-31 Novartis Vaccines & Diagnostic Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
CA2586690A1 (fr) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Vaccination antigrippale
WO2006100111A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
BRPI0721393B8 (pt) * 2007-03-22 2022-09-06 Fund Butantan método para obter lipídeo a monofosforilado da bordetella pertussis como um subproduto da produção de vacina celular contra coqueluche
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP3459563A1 (fr) * 2008-03-18 2019-03-27 Seqirus UK Limited Améliorations dans la préparation d'antigènes de vaccin contre le virus de la grippe
WO2012032482A1 (fr) 2010-09-07 2012-03-15 Novartis Ag Tests génériques pour la détection de réovirus de mammifères
EP2653156A1 (fr) * 2012-10-01 2013-10-23 College of Pharmacy of Taif University Composition d'émulsion pharmaceutique et son utilisation
MX2016012166A (es) * 2014-03-25 2017-03-15 The Government Of The Us Secretary Of The Army Metodos para mejorar la potencia de inmunoestimulacion de vacunas adsorbidas con sales de aluminio.
CN112423787A (zh) * 2018-07-10 2021-02-26 思齐乐私人有限公司 团聚物的去除
CN112361796A (zh) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 一种秸秆回收储存前破碎干燥装置
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU627226B2 (en) * 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
EP0550485A1 (fr) * 1990-09-28 1993-07-14 SMITHKLINE BEECHAM BIOLOGICALS s.a. DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT
EP0563091A1 (fr) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0761231T3 (da) * 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser

Also Published As

Publication number Publication date
IL108681A0 (en) 1994-05-30
MA23118A1 (fr) 1994-10-01
CA2156525A1 (fr) 1994-09-01
AU6141094A (en) 1994-09-14
WO1994019013A1 (fr) 1994-09-01
AP9400621A0 (en) 1994-04-30
MX9401225A (es) 1994-08-31
EP0684838A1 (fr) 1995-12-06
AP431A (en) 1995-11-15

Similar Documents

Publication Publication Date Title
SI9400085A (en) Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza
ES2337901T3 (es) Vacuna de subunidad contra infeccion por el virus respiratorio sincicial.
JP6062245B2 (ja) 組換えｒｓｖ抗原
US10030053B2 (en) Immunogenic compositions and methods of use thereof
ES2307494T3 (es) Vacuna del virus de la gripe inactivo para su administracion via nasalu oral.
CN111375055B (zh) 一种2019-nCoV亚单位疫苗组合物及其免疫方法
BRPI0815008B1 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
CA2169297C (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
TWI329130B (en) Functionally reconstituted viral membranes containing adjuvant
HU226214B1 (en) Vaccines with an ltb adjuvant
US12234263B2 (en) Influenza vaccines
JP2018172417A (ja) 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
JP2015525794A (ja) 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
ES2338382T3 (es) Vacuna intranasal antigripal basada en virosomas.
Kimoto Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant
PL206260B1 (pl) Immunogenna kompozycja liposomowa, jej zastosowanie, sposoby jej wytwarzania i kompozycja szczepionki
WO2016039620A2 (fr) Virosomes du virus respiratoire syncytial